Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

@article{Yasuda2012PreclinicalRF,
  title={Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.},
  author={Hiroyuki Yasuda and Lorena L{\^o}bo de Figueiredo-Pontes and Susumu S Kobayashi and Daniel Botelho Costa},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2012},
  volume={7 7},
  pages={1086-90}
}
INTRODUCTION Most clinically available small-molecule kinase inhibitors are multi-targeted and can inhibit multiple kinases. Our driving hypothesis was that one of these multi-targeted tyrosine kinase inhibitors (TKIs) would have antiproliferative activity against ROS1 translocated non-small-cell lung cancer (NSCLC). METHODS We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
44 Citations
16 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Similar Papers

Loading similar papers…